Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)
India · Delayed Price · Currency is INR 57.77
+0.23 (0.40%)
Sep 24, 2026, 3:26 PM IST
NSE:KREBSBIO Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 252.34 | 237.32 | 433.12 | 504.22 | 521.34 | 597.03 |
| 252.34 | 237.32 | 433.12 | 504.22 | 521.34 | 597.03 | |
Revenue Growth | -29.72% | -45.21% | -14.10% | -3.29% | -12.68% | 13.32% |
Cost of Revenue | 5.13 | 13.21 | 100.31 | 93.99 | 277.16 | 441.18 |
Gross Profit | 247.22 | 224.11 | 332.81 | 410.23 | 244.19 | 155.85 |
Selling, General & Admin | 104.16 | 107.59 | 172.59 | 170.53 | 165.32 | 159.81 |
Other Operating Expenses | 146.7 | 151.96 | 306.24 | 323.98 | 231.74 | 328.01 |
Operating Expenses | 314.99 | 323.78 | 545.72 | 562.17 | 462.65 | 550.79 |
Operating Income | -67.77 | -99.68 | -212.91 | -151.95 | -218.46 | -394.94 |
Interest Expense | -73.16 | -70.85 | -59.08 | -46.86 | -29.71 | -53.85 |
Interest & Investment Income | - | 1.46 | 1.59 | 1.56 | 1.27 | 3.58 |
Other Non Operating Income (Expenses) | - | 18.53 | -0.06 | -0.04 | -0.02 | -0.06 |
EBT Excluding Unusual Items | -140.94 | -150.53 | -270.46 | -197.28 | -246.92 | -445.27 |
Gain (Loss) on Sale of Assets | - | - | 1.22 | - | - | - |
Asset Writedown | - | -18.8 | - | - | - | - |
Pretax Income | -140.94 | -169.33 | -269.24 | -197.28 | -246.92 | -445.27 |
Income Tax Expense | - | - | 0.15 | - | - | - |
Net Income | -140.94 | -169.33 | -269.39 | -197.28 | -246.92 | -445.27 |
Net Income to Common | -140.94 | -169.33 | -269.39 | -197.28 | -246.92 | -445.27 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 22 | 22 | 22 | 22 | 22 | 22 |
Shares Outstanding (Diluted) | 22 | 22 | 22 | 22 | 22 | 22 |
Shares Change | 0.06% | - | - | - | - | 9.89% |
EPS (Basic) | -6.53 | -7.85 | -12.49 | -9.15 | -11.45 | -20.65 |
EPS (Diluted) | -6.53 | -7.85 | -12.49 | -9.15 | -11.45 | -20.65 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -50.92 | -114.54 | -70.5 | -398.71 | -442.95 |
Free Cash Flow Per Share | - | -2.36 | -5.31 | -3.27 | -18.49 | -20.54 |
Gross Margin | 97.97% | 94.43% | 76.84% | 81.36% | 46.84% | 26.11% |
Operating Margin | -26.86% | -42.00% | -49.16% | -30.14% | -41.90% | -66.15% |
Profit Margin | -55.85% | -71.35% | -62.20% | -39.13% | -47.36% | -74.58% |
Free Cash Flow Margin | - | -21.46% | -26.45% | -13.98% | -76.48% | -74.19% |
EBITDA | -3.75 | -37.28 | -147.86 | -86.12 | -154.71 | -338.36 |
EBITDA Margin | -1.48% | -15.71% | -34.14% | -17.08% | -29.68% | -56.67% |
D&A For EBITDA | 64.03 | 62.39 | 65.05 | 65.82 | 63.75 | 56.58 |
EBIT | -67.77 | -99.68 | -212.91 | -151.95 | -218.46 | -394.94 |
EBIT Margin | -26.86% | -42.00% | -49.16% | -30.14% | -41.90% | -66.15% |
Revenue as Reported | 274.05 | 257.58 | 440.21 | 508.73 | 527.55 | 608.59 |